Larvol Delta - MyMD-Pharmaceuticals-Reports-Statistically-Signicant-Positive-Topline-Phase-2-Results-for-Next-Generation-Oral-TNF-Inhibitor-MYMD1-in-SarcopeniaAgeRelated-Frailty

isomyosamine (MYMD-1) - MyMD Pharma, Akers Biosci

https://www.businesswire.com/news/home/20230731983609/en/MyMD-Pharmaceuticals-Reports-Statistically-Significant-Positive-Topline-Phase-2-Results-for-Next-Generation-Oral-TNF-%CE%B1-Inhibitor-MYMD-1%C2%AE-in-SarcopeniaAge-Related-Frailty

Jul 31, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next